Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2017
Treatment Response in Pediatric Patients With Pseudotumor Cerebri Syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tovia Eliel, Reif Shimon, Oren Asaf, Mitelpunkt Alexis, Fattal-Valevski Aviva
Аннотация
BACKGROUND: Pseudotumor cerebri syndrome (PTCS) is a disorder defined by increased intracranial pressure in the absence of an intracranial space-occupying lesion. This retrospective study aimed to examine the outcomes in children with PTCS.
METHODS: Data was collected retrospectively from the charts of consecutive pediatric patients treated for PTCS at our hospital between 2000 and 2007 (60 patients; 36 females, 24 males).
RESULTS: Forty-six patients (76.6%) responded well to acetazolamide therapy, with full resolution of symptoms, including papilledema (average treatment duration 1 year; range: 1 month-5 years). Of the 14 patients with no response to treatment, 9 (23.4%) required surgical intervention. Nonresponders tended to be younger at presentation (8.7 vs 11.5 years, P = 0.04). Twelve patients (26%) experienced relapse after acetazolamide was discontinued. The group that experienced relapse was significantly younger than the nonrelapsers (8.9 vs 12.1 years, P < 0.05).
CONCLUSIONS: Younger age at presentation with PTCS was found to be a risk factor for treatment failure or relapse.
METHODS: Data was collected retrospectively from the charts of consecutive pediatric patients treated for PTCS at our hospital between 2000 and 2007 (60 patients; 36 females, 24 males).
RESULTS: Forty-six patients (76.6%) responded well to acetazolamide therapy, with full resolution of symptoms, including papilledema (average treatment duration 1 year; range: 1 month-5 years). Of the 14 patients with no response to treatment, 9 (23.4%) required surgical intervention. Nonresponders tended to be younger at presentation (8.7 vs 11.5 years, P = 0.04). Twelve patients (26%) experienced relapse after acetazolamide was discontinued. The group that experienced relapse was significantly younger than the nonrelapsers (8.9 vs 12.1 years, P < 0.05).
CONCLUSIONS: Younger age at presentation with PTCS was found to be a risk factor for treatment failure or relapse.
Предметные рубрики MeSH
AcetazolamideAdolescentBrainChildChild, PreschoolDiureticsDrug Therapy, CombinationFemaleFollow-Up StudiesForecastingFructoseFurosemideGlucocorticoidsHumansIntracranial PressureMagnetic Resonance ImagingMaleNeuroprotective AgentsPseudotumor CerebriRetrospective StudiesSpinal PunctureTopiramateTreatment Outcome